Joyzyme Group Limited, trading as HUAKANG BIOMED (Stock Code: 08622), has announced that its board of directors will convene on 27 March 2026. The agenda includes:

• Reviewing and approving the audited consolidated financial results for the year ended 31 December 2025. • Considering the declaration and payment of a final dividend, if any. • Addressing other routine corporate matters.

The board currently consists of four Executive Directors—Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; two Non-executive Directors—Dr. Bu Su and Dr. Xu Ming; and three Independent Non-executive Directors—Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.

The company confirms that all information in the announcement is accurate and complete to the best of the directors’ knowledge. The notice will remain available on the Hong Kong Stock Exchange website and the company’s website for at least seven days from the publication date of 17 March 2026.